|Original language||English (US)|
|Title of host publication||Stroke|
|Number of pages||22|
|State||Published - 2011|
ASJC Scopus subject areas
- Clinical Neurology
- Cardiology and Cardiovascular Medicine
- Advanced and Specialized Nursing
Access to Document
Other files and links
Interventional Neuroradiologic Therapy of Atherosclerotic Disease and Vascular Malformations. / Mocco, J.; Kim, Stanley H.; Bendok, Bernard R.; Boulos, Alan S.; Hopkins, L. Nelson; Levy, Elad I.Stroke. Elsevier Inc., 2011. p. 1204-1225.
Research output: Chapter in Book/Report/Conference proceeding › Chapter
TY - CHAP
T1 - Interventional Neuroradiologic Therapy of Atherosclerotic Disease and Vascular Malformations
AU - Mocco, J.
AU - Kim, Stanley H.
AU - Bendok, Bernard R.
AU - Boulos, Alan S.
AU - Hopkins, L. Nelson
AU - Levy, Elad I.
N1 - Funding Information: The authors have the following financial relationships to disclose: Dr. Bendok has received research funding from Cordis; Dr. Mocco serves as a consultant to Actelion, Nfocus, and Lazarus Effect; his employer, The University of Florida, receives research funding from AccessClosure and Codman Neurovascular. Dr. Hopkins receives research study grants from Abbott (ACT 1 Choice), Boston Scientific (CABANA), Cordis (SAPPHIRE WW), and ev3/Covidien Vascular Therapies (CREATE) and a research grant from Toshiba (for the Toshiba Stroke Research Center); has an ownership/financial interest in AccessClosure, Boston Scientific, Cordis, Micrus, and Valor Medical; serves on the Abbott Vascular Speakers’ Bureau; receives honoraria from Bard, Boston Scientific, Cordis, and from the following for speaking at conferences—Complete Conference Management, Cleveland Clinic, and SCAI; receives royalties from Cordis (for the AngioGuard device), serves as a consultant to or on the advisory board for Abbott, AccessClosure, Bard, Boston Scientific, Cordis, Gore, Lumen Biomedical, Micrus, and Toshiba; and serves as the conference director for Nurcon Conferences/Strategic Medical Seminars LLC. Dr. Levy receives research grant support (principal investigator: Stent-Assisted Recanalization in acute Ischemic Stroke, SARIS), other research support (devices), and honoraria from Boston Scientific and research support from Micrus Endovascular and ev3/Covidien Vascular Therapies; has ownership interests in Intratech Medical Ltd. and Mynx/AccessClosure; serves as a consultant on the board of Scientific Advisors to Codman & Shurtleff, Inc.; serves as a consultant per project and/or per hour for Micrus Endovascular, ev3/Covidien Vascular Therapies, and TheraSyn Sensors, Inc.; and receives fees for carotid stent training from Abbott Vascular and ev3/Covidien Vascular Therapies. Dr. Levy receives no consulting salary arrangements. All consulting is per project, per hour, or both. Funding Information: Both EVA-3S and SPACE have reported equivalent rates of mortality and stroke prevention for CAS and CEA at the 2-year (SPACE Trial (CREST), a prospective, randomized, multicenter, trial funded by the National Institutes of Health (NIH), were anxiously awaited to help determine the potential roles of CAS and CEA in the treatment of patients with extracranial carotid artery atherosclerosis. 119 ) and 4-year (EVA-3S 120 ) follow-up periods. With the state of evidence for CAS being subject to conflicting data of variable quality, the results of the Carotid Revascularization Endarterectomy vs. Stenting
PY - 2011
Y1 - 2011
UR - http://www.scopus.com/inward/record.url?scp=84882921397&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84882921397&partnerID=8YFLogxK
U2 - 10.1016/B978-1-4160-5478-8.10061-2
DO - 10.1016/B978-1-4160-5478-8.10061-2
M3 - Chapter
AN - SCOPUS:84882921397
SN - 9781416054788
SP - 1204
EP - 1225
BT - Stroke
PB - Elsevier Inc.